Back to Sectors

CLDI

Calidi Biotherapeutics, Inc.
4 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BEARISH | 90% | 3/27/2026 | capital raiseBEARISH | 70% | 3/27/2026 | margin compressionBEARISH | 95% | 3/27/2026 | dilution riskBULLISH | 60% | 3/27/2026 | regulatory actionBEARISH | 70% | 5/14/2026 | earnings missBULLISH | 50% | 5/14/2026 | capital raiseBEARISH | 90% | 5/14/2026 | dilution riskBULLISH | 40% | 5/14/2026 | margin expansionBEARISH | 70% | 5/14/2026 | earnings missBULLISH | 50% | 5/14/2026 | capital raiseBEARISH | 90% | 5/14/2026 | dilution riskBULLISH | 40% | 5/14/2026 | margin expansionBEARISH | 70% | 5/29/2026 | dilution riskNEUTRAL | 40% | 5/29/2026 | capital raiseMar 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 29

Potential issuance of 17.4 million shares at a low exercise price of $0.23.

dilution risk
70%
neutralMay 29

Amended warrant agreement to manage investor relations and acquisition triggers.

capital raise
40%
bearishMay 14

Company continues to report significant net losses with a $4.1M loss this quarter.

earnings miss
70%
bullishMay 14

Raised $5.1M in net proceeds from a March 2026 public offering to extend runway.

capital raise
50%
bearishMay 14

Massive warrant overhang of 49.4M shares with exercise prices reset to $0.50.

dilution risk
90%
bullishMay 14

G&A expenses decreased by 39% year-over-year, showing improved cost discipline.

margin expansion
40%
bearishMay 14

Company continues to report significant net losses with a $4.1M loss this quarter.

earnings miss
70%
bullishMay 14

Raised $5.1M in net proceeds from a March 2026 public offering to extend runway.

capital raise
50%
bearishMay 14

Massive warrant overhang of 49.4M shares with exercise prices reset to $0.50.

dilution risk
90%
bullishMay 14

G&A expenses decreased by 39% year-over-year, showing improved cost discipline.

margin expansion
40%
bearishMar 27

Company is dependent on future equity raises to avoid insolvency due to critical cash shortage.

capital raise
90%
bearishMar 27

Significant net losses of $20.1M in 2025 against minimal cash reserves.

margin compression
70%
bearishMar 27

History of multiple reverse splits and low-priced offerings causing severe shareholder dilution.

dilution risk
95%
bullishMar 27

Secured FDA Fast Track Designation for CLD-201 in soft tissue sarcoma.

regulatory action
60%

Filing History

8-KMay 29, 2026

Calidi Biotherapeutics' 8-K filing reveals a complex restructuring of a private placement warrant that balances immediate stability against long-term dilution. The shift in vesting terms and the addition of a stockholder vote requirement suggest a tension between the need for capital and the desire to protect share price. Investors must now weigh whether these changes represent a sophisticated play for a higher valuation or a desperate attempt to buy time in a challenging funding environment for pre-clinical biotech.

10-QMay 14, 2026

The latest 10-Q reveals a company at a critical juncture, balancing a promising technological breakthrough against a fragile balance sheet. While the RedTail platform represents a potential paradigm shift in treating metastatic disease, the financial reality is one of survival. The reduction in operating losses is a positive signal, but it is overshadowed by the explicit warning regarding the company's ability to continue as a going concern. Ultimately, the investment case for Calidi has shifted from a long-term platform play to a high-stakes binary bet on the CLD-401 IND filing and the company's ability to secure non-dilutive or minimally dilutive funding. The tension between the scientific potential of the RedTail platform and the imminent need for capital creates a volatile risk-reward profile for shareholders.

10-KMar 27, 2026

Calidi Biotherapeutics represents a classic high-risk, high-reward biotech play where cutting-edge science is colliding with critical liquidity constraints. The RedTail platform offers a potentially transformative approach to metastatic cancer, but the company's ability to reach its 2026 clinical milestones is entirely dependent on its ability to raise more capital at a time when its stock price is under severe pressure. Investors are essentially betting on whether the company can secure a strategic partnership or a fresh equity infusion before its current cash runway expires. While the technical milestones and FDA Fast Track designations provide a glimmer of hope, the structural instability of the balance sheet and the history of aggressive dilution make this a highly speculative venture. The coming months will be decisive in determining if Calidi is a viable platform or a cautionary tale of capital exhaustion.